AbbVie (ABBV) Liabilities and Shareholders Equity (2012 - 2026)

AbbVie (ABBV) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $136.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.22% year-over-year to $136.5 billion; the TTM figure through Mar 2026 stood at $541.5 billion (down 2.73% YoY), while the FY2025 annual figure was $134.0 billion, down 0.89% from the prior year.
• Liabilities and Shareholders Equity advanced to $136.5 billion in Q1 2026 per ABBV's latest filing, from $134.0 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $148.9 billion in Q1 2024 and bottomed at $133.9 billion in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $138.5 billion across 5 years, with a median of $136.5 billion in 2026.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity increased 10.65% — and 2025, when it retreated 8.54%.
• AbbVie's Liabilities and Shareholders Equity stood at $138.8 billion in 2022, then slipped by 2.95% to $134.7 billion in 2023, then grew by 0.33% to $135.2 billion in 2024, then declined by 0.89% to $134.0 billion in 2025, then increased by 1.87% to $136.5 billion in 2026.
• Business Quant data shows ABBV's Liabilities and Shareholders Equity at $136.5 billion in Q1 2026, $134.0 billion in Q4 2025, and $133.9 billion in Q3 2025.